Preclinical data with BBT002 demonstrate its best-in-disease potential for improved efficacy and dosing convenience across respiratory, dermatology, and gastroenterology indications Interim safety and pharmacokinetic data from BBT002-01 study anticipated in Q1 2026 The clearance of...
Read More Details
Finally We wish PressBee provided you with enough information of ( Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001 )
Also on site :
- The Best Things to Do in Italy's 'Boot Region,' According to an Apulian Tour Guide
- Child and two adults killed in M5 crash as road remains closed
- India top general admits ‘losses’ in recent conflict with Pakistan